SG11202104518WA - Pharmaceutical combination of anti ceacam6 and tim3 antibodies - Google Patents
Pharmaceutical combination of anti ceacam6 and tim3 antibodiesInfo
- Publication number
- SG11202104518WA SG11202104518WA SG11202104518WA SG11202104518WA SG11202104518WA SG 11202104518W A SG11202104518W A SG 11202104518WA SG 11202104518W A SG11202104518W A SG 11202104518WA SG 11202104518W A SG11202104518W A SG 11202104518WA SG 11202104518W A SG11202104518W A SG 11202104518WA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical combination
- tim3 antibodies
- ceacam6
- anti ceacam6
- tim3
- Prior art date
Links
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 title 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18214059 | 2018-12-19 | ||
| PCT/EP2019/084849 WO2020126808A1 (en) | 2018-12-19 | 2019-12-12 | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104518WA true SG11202104518WA (en) | 2021-05-28 |
Family
ID=65009547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104518WA SG11202104518WA (en) | 2018-12-19 | 2019-12-12 | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220089721A1 (es) |
| EP (1) | EP3897844B1 (es) |
| JP (1) | JP2022513246A (es) |
| KR (1) | KR20210104704A (es) |
| CN (1) | CN113164778A (es) |
| AU (1) | AU2019407364A1 (es) |
| BR (1) | BR112021007968A2 (es) |
| CA (1) | CA3123735A1 (es) |
| IL (1) | IL283746B1 (es) |
| MX (1) | MX2021007369A (es) |
| SG (1) | SG11202104518WA (es) |
| WO (1) | WO2020126808A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023031366A1 (en) | 2021-09-02 | 2023-03-09 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| DE8808645U1 (es) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen, De | |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| US10131712B2 (en) * | 2012-08-14 | 2018-11-20 | Ibc Pharmaceuticals, Inc. | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors |
| CN105073128A (zh) * | 2013-04-03 | 2015-11-18 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015126548A1 (en) * | 2014-02-21 | 2015-08-27 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
| EP3628688A1 (en) | 2015-03-23 | 2020-04-01 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
| MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
| US11390674B2 (en) | 2016-04-12 | 2022-07-19 | Symphogen A/S | Anti-TIM-3 antibodies and compositions |
| AU2017271588B2 (en) | 2016-05-27 | 2022-01-20 | Agenus Inc. | Anti-TIM-3 antibodies and methods of use thereof |
| WO2017210058A1 (en) * | 2016-06-01 | 2017-12-07 | Ibc Pharmaceuticals, Inc. | Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors |
| EP3484920A2 (en) | 2016-07-14 | 2019-05-22 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| AU2018205401A1 (en) | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| SG11202105078XA (en) * | 2018-11-14 | 2021-06-29 | Bayer Ag | Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer |
-
2019
- 2019-12-12 JP JP2021534355A patent/JP2022513246A/ja active Pending
- 2019-12-12 AU AU2019407364A patent/AU2019407364A1/en active Pending
- 2019-12-12 WO PCT/EP2019/084849 patent/WO2020126808A1/en unknown
- 2019-12-12 SG SG11202104518WA patent/SG11202104518WA/en unknown
- 2019-12-12 BR BR112021007968-8A patent/BR112021007968A2/pt not_active Application Discontinuation
- 2019-12-12 CA CA3123735A patent/CA3123735A1/en active Pending
- 2019-12-12 EP EP19816755.3A patent/EP3897844B1/en active Active
- 2019-12-12 US US17/416,958 patent/US20220089721A1/en active Pending
- 2019-12-12 KR KR1020217018157A patent/KR20210104704A/ko unknown
- 2019-12-12 IL IL283746A patent/IL283746B1/en unknown
- 2019-12-12 CN CN201980078825.6A patent/CN113164778A/zh active Pending
- 2019-12-12 MX MX2021007369A patent/MX2021007369A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021007968A2 (pt) | 2021-09-08 |
| MX2021007369A (es) | 2021-07-15 |
| EP3897844A1 (en) | 2021-10-27 |
| IL283746A (en) | 2021-07-29 |
| JP2022513246A (ja) | 2022-02-07 |
| EP3897844C0 (en) | 2023-11-15 |
| KR20210104704A (ko) | 2021-08-25 |
| CN113164778A (zh) | 2021-07-23 |
| WO2020126808A1 (en) | 2020-06-25 |
| US20220089721A1 (en) | 2022-03-24 |
| IL283746B1 (en) | 2024-04-01 |
| EP3897844B1 (en) | 2023-11-15 |
| AU2019407364A1 (en) | 2021-05-27 |
| CA3123735A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004494B (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| IL278846A (en) | Anti-CD3 antibodies and uses thereof | |
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| EP3621642A4 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES | |
| IL269593A (en) | Anti-ILT4 antibodies and antigen-binding fragments | |
| IL272274A (en) | Antibodies 4H-7B methods for their use | |
| IL279974A (en) | Anti-BCMA and anti-CD3 bispecific antibodies and their uses | |
| IL276277A (en) | Anti-CTLA4 antibodies and methods for their preparation and use | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| IL276790A (en) | b7-h4 antibodies and methods of using them | |
| IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
| IL270214A (en) | Anti-sortilin antibodies and methods of using them | |
| IL278772A (en) | Antibodies against 40-OX and methods of use | |
| SG11202106498XA (en) | Anti-ctla4 antibodies and methods of use thereof | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| IL283884A (en) | Antibodies against il-36 and methods of using them | |
| IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them | |
| EP3676294A4 (en) | ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF | |
| EP3645738A4 (en) | ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF | |
| IL277296A (en) | Antibodies against PFRH5 and their antigen-binding fragments | |
| IL283746A (en) | Pharmaceutical combination of anti-ceacam6 and tim3 antibodies | |
| IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them | |
| IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use | |
| EP3893930A4 (en) | MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND THEIR USES |